Results for tag: "Naftopidil"

Naftopidil is a drug used to treat urological disorders, such as benign prostatic hyperplasia (BPH). It is a selective alpha-1A adrenergic receptor antagonist, which works by relaxing the muscles in the prostate and bladder neck, allowing for improved urine flow. It is available in both oral and topical formulations, and is often used in combination with other drugs to treat BPH. Naftopidil is a relatively new drug, having been approved by the FDA in the United States in 2018. It is currently approved in several countries, including Japan, South Korea, and Taiwan. It is also being studied for its potential use in other urological disorders, such as overactive bladder. The market for Naftopidil is growing, as it is becoming increasingly recognized as an effective treatment for BPH. It is also becoming more widely available, with more countries approving its use. Some companies in the Naftopidil market include Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Ltd., and Daiichi Sankyo Company, Ltd. Show Less Read more